Variable | TCGA LUAD | TCGA SKCM | TCGA HNSC | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Subtypes | HH | HL | LH | LL | P | HH | HL | LH | LL | P | HH | HL | LH | LL | P |
Gender (%)/Chi-squared test | Â | Â | Â | Â | 0.35 | Â | Â | Â | Â | 0.14 | Â | Â | Â | Â | 0.0016** |
 Male | 41 (43.2) | 66 (42.6) | 75 (48.4) | 51 (53.1) |  | 47 (58.0) | 53 (55.8) | 66 (69.5) | 55 (67.9) |  | 76 (75.2) | 102 (65.4) | 131 (84.0) | 70 (69.3) |  |
 Female | 54 (56.8) | 89 (57.4) | 80 (51.6) | 45 (46.9) |  | 34 (42.0) | 42 (44.2) | 29 (30.5) | 26 (32.1) |  | 25 (24.8) | 54 (34.6) | 25 (16.0) | 31 (30.7) |  |
Median age (IQR)/ANOVA | 66.5 (57.7–72.2) | 69.4 (62.7–75.0) | 63.3 (56.2–71.6) | 65.3 (60.5–72.0) |  < 0.0001**** | 56.7 (46.4–64.8) | 56.3 (45.0–71.6) | 56.1 (49.0–68.7) | 60.0 (46.4–70.9) | 0.71 | 60.77 (53.51–68.99) | 61.11 (55.03–69.86) | 60.85 (53.03–67.88) | 61.72 (53.04–69.02) | 0.72 |
Pathologic T (%)/Chi-squared test | Â | Â | Â | Â | 0.16 | Â | Â | Â | Â | 0.068 | Â | Â | Â | Â | 0.018* |
 T0–2 | 86 (90.5) | 139 (90.8) | 129 (83.8) | 81 (84.4) |  | 38 (58.5) | 39 (52.0) | 35 (45.5) | 24 (36.4) |  | 37 (41.1) | 64 (48.5) | 41 (30.0) | 40 (43.0) |  |
 T3–4 | 9 (9.5) | 14 (9.2) | 25 (16.2) | 15 (15.6) |  | 27 (41.5) | 36 (48.0) | 42 (54.5) | 42 (63.6) |  | 53 (58.9) | 68 (51.5) | 96 (70.0) | 53 (57.0) |  |
Pathologic N (%)/Chi-squared test |  |  |  |  |  < 0.0001**** |  |  |  |  | 0.3 |  |  |  |  | 0.42 |
 N0–1 | 81 (85.3) | 139 (93.9) | 115 (75.2) | 83 (88.3) |  | 50 (68.5) | 66 (77.6) | 59 (68.6) | 55 (78.6) |  | 40 (49.4) | 71 (60.2) | 77 (58.8) | 51 (60.0) |  |
 N2–3 | 14 (14.7) | 9 (6.1) | 38 (24.8) | 11 (11.7) |  | 23 (31.5) | 19 (22.4) | 27 (31.4) | 15 (21.4) |  | 41 (50.6) | 47 (39.8) | 54 (41.2) | 34 (40.0) |  |
Pathologic M (%)/Fisher's test | Â | Â | Â | Â | 0.3 | Â | Â | Â | Â | 0.27 | Â | Â | Â | Â | 0.16 |
 M0 | 69 (94.5) | 95 (96.0) | 105 (92.1) | 63 (88.7) |  | 70 (93.3) | 86 (96.6) | 87 (94.6) | 64 (88.9) |  | 40 (100) | 56 (100) | 57 (100) | 29 (96.7) |  |
 M1 | 4 (5.5) | 4 (4.0) | 9 (7.9) | 8 (11.3) |  | 5 (6.7) | 3 (3.4) | 5 (5.4) | 8 (11.1) |  | 0 | 0 | 0 | 1 (3.3) |  |
Pathologic stage (%)/Chi-squared test |  |  |  |  |  < 0.0001**** |  |  |  |  | 0.38 |  |  |  |  | 0.16 |
 Stage I | 47 (49.5) | 106 (69.3) | 64 (41.3) | 54 (56.3) |  | 19 (25.7) | 24 (28.9) | 18 (19.8) | 14 (19.4) |  | 2 (2.2) | 11 (8.5) | 5 (3.7) | 9 (9.9) |  |
 Stage II | 28 (29.5) | 31 (20.3) | 43 (27.7) | 19 (19.8) |  | 12 (16.2) | 19 (22.9) | 29 (31.9) | 23 (31.9) |  | 13 (14.6) | 28 (21.7) | 17 (12.6) | 15 (16.5) |  |
 Stage III | 16 (16.8) | 11 (7.2) | 39 (25.2) | 14 (14.6) |  | 38 (51.4) | 37 (44.6) | 39 (42.9) | 28 (38.9) |  | 18 (20.2) | 20 (15.5) | 24 (17.8) | 17 (18.7) |  |
 Stage IV | 4 (4.2) | 5 (3.3) | 9 (5.8) | 9 (9.4) |  | 5 (6.8) | 3 (3.6) | 5 (5.5) | 7 (9.7) |  | 56 (62.9) | 70 (54.3) | 89 (65.9) | 50 (54.9) |  |
Survival rate (%)/log-rank |  |  |  |  |  < 0.0001**** |  |  |  |  |  < 0.0001**** |  |  |  |  | 0.39 |
 3-year OS | 60.7 | 78.4 | 45.5 | 69.2 |  | 75 | 85.1 | 60.8 | 79.4 |  | 56.2 | 65.6 | 52.7 | 54.4 |  |
 5-year OS | 41.2 | 55 | 30.2 | 40.1 |  | 65.1 | 78.4 | 43.2 | 63.3 |  | 46.2 | 50.3 | 47 | 47.4 |  |